Search - tctmd.com

Displaying 101 - 120 of 532

Sort: Relevancy | Date

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Caitlin E. Cox

August 21, 2019

Presentation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

August 20, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Features

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

Yael L. Maxwell

August 02, 2019

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Todd Neale

July 29, 2019

News Daily News

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Michael O'Riordan

July 10, 2019

News Conference News TVT 2019

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Michael O'Riordan

June 20, 2019

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

News Conference News TVT 2019

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Michael O'Riordan

June 17, 2019

News Conference News TVT 2019

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

Shelley Wood

June 13, 2019

News Conference News SCAI 2019

TAVR Operators: Can One Do It All or Are Two Still Justified?

Yael L. Maxwell

June 04, 2019

News Conference News EuroPCR 2019

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Shelley Wood

May 23, 2019

News Conference News EuroPCR 2019

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

Michael O'Riordan

May 22, 2019

News Daily News

Latest Observational Data Support TAVR Durability Through 7 Years

Caitlin E. Cox

April 12, 2019

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Daily News

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

L.A. McKeown

March 29, 2019

Presentation CIT 2019

PARTNER 3 and TAVR Trials

Presenter: Rebecca T. Hahn

March 28, 2019

News Daily News

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Michael O'Riordan

March 27, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Presentation ACC 2019

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Presenter: Martin B. Leon

March 17, 2019

Advertisement

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

FDA Expands TAVR Indication to Low-Risk Patients

Structural Heart Hype: As Fellowship Programs Mushroom, Who’s Keeping Tabs on Quality and Numbers?

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

Evolut Valves: Initial Positioning Can Be Optimized for Future Coronary Access

Better Hemodynamics, Less Mismatch With Self-Expanding TAVR vs Surgery

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

TAVR Operators: Can One Do It All or Are Two Still Justified?

TAVR’s Benefit Across ‘Spectrum of Risk’ Supports Paradigm Shifts, Says EuroPCR Statement

Longer Follow-up ‘Reassuring’ for New-Onset LBBB After TAVR—With Caveats

Latest Observational Data Support TAVR Durability Through 7 Years

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

PARTNER 3 and TAVR Trials

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

PARTNER 3: Transcatheter or Surgical Aortic Valve Replacement in Low Risk Patients with Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content